Yüklüyor......
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
The phosphatidylinositol 3-kinase signal transduction pathway members are often activated in tumor samples from patients with non-Hodgkin's lymphoma (NHL). Everolimus is an oral agent that targets the raptor mammalian target of rapamycin (mTORC1). The goal of this trial was to learn the antitum...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Publishing Group
2011
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3049870/ https://ncbi.nlm.nih.gov/pubmed/21135857 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2010.226 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|